Anna Nijdam Sells 5,501 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 5,501 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.74, for a total transaction of $169,100.74. Following the completion of the sale, the insider owned 48,945 shares in the company, valued at approximately $1,504,569.30. This trade represents a 10.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The shares were sold at an average price of $30.60, for a total transaction of $55,967.40.

Pharvaris Stock Performance

PHVS stock opened at $29.47 on Thursday. The firm has a 50 day moving average price of $28.66 and a 200-day moving average price of $27.01. Pharvaris N.V. has a 52-week low of $15.46 and a 52-week high of $33.33. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.27 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, sell-side analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in Pharvaris in the 4th quarter worth about $35,000. JPMorgan Chase & Co. lifted its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the 3rd quarter valued at about $75,000. Barclays PLC purchased a new stake in shares of Pharvaris during the 4th quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris during the 4th quarter valued at about $86,000.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several recent analyst reports. Citizens Jmp lowered their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wedbush upped their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Short interest in Pharvaris fell sharply in mid-May, dropping 42.9% to 600,645 shares. That lower bearish positioning can be viewed as a constructive signal for the stock.
• Positive Sentiment: Brokerage coverage remains supportive, with Pharvaris receiving a consensus rating of “Moderate Buy,” which suggests analysts still see meaningful upside potential. Article link
• Neutral Sentiment: The company also continues to trade near the upper end of its 52-week range after beating first-quarter EPS estimates, which helps reinforce investor confidence in the name. Article link
• Negative Sentiment: Recent insider selling by CFO David Nassif, Director Viviane Monges, and insider Anna Nijdam may be pressuring sentiment, even though some of the sales were tied to tax withholding or equity vesting. Article link

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.